Detection of Plasmodium falciparum chloroquine resistance transporter (PfCRT) mutant gene amongst malaria-infected pregnant women in Calabar, Nigeria

• Autorzy: Monjol B.E. , Useh M.F.
• Języki publikacji: EN

Abstrakty

EN

Chemotherapy is the mainstay in malaria control and management. For some time, chloroquine (CQ) was a drug of choice for the treatment of malaria. It was effective against all forms of malaria, cheap and readily available. The increased resistance of malaria parasites to CQ led to widespread abandonment of the drug in African and Asian countries on the prompting of the World Health Organization. Currently, artemisinin-based combination therapy is the gold standard for the treatment of malaria. This study investigates the presence of the Plasmodium falciparum Chloroquine Resistance Transporter (PfCRT) mutant gene, a molecular marker responsible for CQ resistance in malaria parasites. A total of 369 pregnant women were microscopically screened for malaria infection using thin and thick blood films stained with Giemsa. Subsequently, malaria parasite DNA was extracted from the blood of malaria positive participants. The PfCRT gene was amplified using Polymerase Chain Reaction (PCR). A Restriction Fragment Length Polymorphism analysis of the gene was performed to confirm mutant forms. The results showed that 251 (68.0%) of the participants had Plasmodium falciparum in their blood. Molecular examination revealed the presence of PfCRT mutant genes in 28% of the study population. Notwithstanding the decline in the prevalence of PfCRT T76 mutation since the antimalarial policy change in Nigeria, the 28% prevalence recorded in this study is considered high after ten years of the withdrawal of CQ in the treatment of uncomplicated malaria.

• Wydawca: -
• Czasopismo: Annals of Parasitology
• Rocznik: 2017
• Tom: 63
• Numer: 4
• Opis fizyczny: p.323-330,fig.,ref.

Twórcy

autor

Monjol B.E.

• Medical Microbiology Unit, Department of Medical Laboratory Science, University of Calabar, Cross River State, Nigeria

autor

Useh M.F.

• Medical Parasitology Unit, Department of Medical Laboratory Science, University of Calabar, Cross River State, Nigeria

Bibliografia

• [1] World Health Organization. 2007. The world health report. World Health Organization, Geneva, Switzerland.
• [2] Olliaro P., Cattani J., Wirth D. 1996. Malaria, the submerged disease. Journal of American Medical Association 275: 230-233. doi:10.1001/jama.1996.03530270070034
• [3] World Health Organization. 2008. Guidelines for treatment of malaria. World Health Organization, Geneva, Switzerland.
• [4] Federal Ministry of Health. 2012. Roll back malaria partnership. Progress and impact series. Country reports, Abuja, Nigeria.
• [5] Roll Back Malaria. 2011. Malaria prevention and control progress, Annual Report. Progress and Compact Series, Abuja, Nigeria.
• [6] Utzinger J., Tanner M., Kammen D.M., Killeen G.F., Singer B.H. 2002. Integrated programme is key to malaria control. Nature 419: 431. doi:10.1038/419431a
• [7] Geerligs P.D.P., Brabin B.J., Eggelte T.A. 2003. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bulletin of the World Health Organization 81: 205-216.
• [8] Bray P.G., Martin R.E., Tilley L., Ward S.A., Kirk K., Fidock D.A. 2005. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Molecular Microbiology 56: 323-333. doi:10.1111/j.1365-2958.2005.04556.x
• [9] Plowe C.V. 2005. Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. In: Malaria: drugs, disease and post-genomic biology. (Eds. R.W. Compans, M.D. Cooper, T. Honjo, H. Koprowski, F. Melchers, M.B.A. Oldstone, S. Olsnes, M. Potter, P.K. Vogt, H. Wagner, D.J. Sullivan, S. Krishna). Current Topics in Microbiology and Immunology 295: 55-79. https://doi.org/10.1007/3-540-29088-5_3
• [10] Ginsburg H., Famin O., Zhang J., Krugliak M. 1998. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochemical Pharmacology 56: 1305-1313. https://doi.org/10.1016/s0006-2952(98)00184-1
• [11] Trape J.F. 2001. The public health impact of chloroquine resistance in Africa. The American Journal of Tropical Medicine and Hygiene 64 (Suppl. 1): 12-17. https://doi.org/10.4269/ajtmh.2001.64.12
• [12] Umar R.A., Hassan S.W., Ladan M.J., Nma Jiya M., Abubakar M.K., Nata`ala U. 2007. The association of K76T mutation in Pfcrt gene and Chloroquine treatment failure in uncomplicated Plasmodium falciparum malaria in a cohort of Nigerian children. Journal of Applied Sciences 7: 3696-3704. doi:10.3923/jas.2007.3696.3704
• [13] Ezedinachi E.N., Ekanem O.J., Chukwuani C.M., Meremikwu M.M., Ojar E.A., Alaribe A.A., Umotong A.B., Haller L. 1999. Efficacy and tolerability of a low-dose mefloquine-sulphadoxinepyrimethamine combination compared with chloroquine in the treatment of acute malaria infection in a population with multiple drug-resistant Plasmodium falciparum. The American Society of Tropical Medicine and Hygiene 61: 114-119. https://doi.org/10.4269/ajtmh.1999.61.114
• [14] Bloland P.B., Kazembe P.N., Oloo A.J., Himonga B., Barat L.M., Ruebush T.K. 1998. Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa. Tropical Medicine and International Health 3: 543-552. doi:10.1046/j.1365-3156.1998.00270.x
• [15] Mwai L., Ochong E., Abdirahman A., Kiara S.M., Ward S., Kokwaro G., Sasi P., Marsh K., Borrmann S., Mackinnon M., Nzila A. 2009. Chloroquine resistance before and after its withdrawal in Kenya. Malaria Journal 8: 106. https://doi.org/10.1186/1475-2875-8-106
• [16] National Population Commission, Federal Republic of Nigeria. 2009. Nigeria demographic and health survey 2008. Abuja, Nigeria.
• [17] Daniel W.W. 1999. Biostatistics: a foundation for analysis in the health sciences. (Ed. W.W. Daniel), 7th ed., John Wiley & Sons, New York, USA.
• [18] World Health Organization. 2010. Guidelines for the treatment of malaria. 2nd ed., World Health Organization, Geneva, Switzerland.
• [19] Okafor I.M., Akpan P.A., Usanga E.A. 2012. Prevalence and types of anaemia in malaria infected pregnant women attending antenatal clinic in University of Calabar Teaching Hospital, Calabar, Nigeria. Journal of Natural Sciences Research 2: 73-78.
• [20] Ojiezeh T.I., Ibeh N.I., Opedun D.O., Udoh S.J. 2010. Malaria endemicity among pregnant women in urban and semi-urban areas in Southwest, Nigeria. American-Eurasian Journal of Scientific Research 5: 207-211.
• [21] Adefioye O.A., Adeyeba O.A., Hassan W.O. Oyeniran O.A. 2007. Prevalence of malaria parasite infection among pregnant women in Osogbo, Southwest, Nigeria. American-Eurasian Journal of Scientific Research 2: 43-45.
• [22] Olasehinde G.I., Ojurongbe O.O., Fagade E.O., Egwari L.O., Ajayi A.A., Adeyeba O.A., Ruchi S. 2013. Detection of molecular markers of antimalarial drug resistance in Plasmodium falciparum from South-Western Nigeria. Covenant Journal of Physical and Life Sciences 1: 61-75.
• [23] Efunshile M, Runsewe-Abiodun T, Ghebremedhin B., König W., König B. 2011. Prevalence of molecular marker of chloroquine resistance (pfcrt 76) in Nigeria 5 years after withdrawal of the drug as first-line antimalarial: a cross-sectional study. South African Journal of Child Health 5: 39-42.
• [24] Ndiaye M., Faye B., Tine R., Ndiaye J.L., Lo A., Abiola A., Dieng Y., Ndiaye D., Hallett R., Alifrangis M., Gaye O. 2012. Assessment of the molecular marker of Plasmodium falciparum chloroquine resistance (Pfcrt) in Senegal after several years of chloroquine withdrawal. The American Society of Tropical Medicine and Hygiene 87: 640-645. https://doi.org/10.4269/ajtmh.2012.11-0709
• [25] Mohammed A., Ndaro A., Kalinga A., Manjurano A., Mosha J.F., Mosha D.F., van Zwetselaar M., Koenderink J.B., Mosha F.W., Alifrangis M., Reyburn H., Roper C., Kavishe R.A. 2013. Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania. Malaria Journal 12: 415. https://doi.org/10.1186/1475-2875-12-415
• [26] World Health Organization. 2002. Malaria desk situation analysis-Nigeria. World Health Organization, Geneva, Switzerland.

Identyfikatory

DOI

10.17420/ap6304.119